John Pollard; Nicola Curtin Targeting the DNA Damage Response for Anti-Cancer Therapy 9783030093365

Варианты приобретения

Цена: 27950.00р.
Кол-во:
Наличие: Поставка под заказ. Есть в наличии на складе поставщика.
Склад Америка: Есть
При оформлении заказа до: 2025-07-28
Ориентировочная дата поставки: Август-начало Сентября
При условии наличия книги у поставщика.

Добавить в корзину

в Мои желания

Автор: John Pollard; Nicola Curtin
Название: Targeting the DNA Damage Response for Anti-Cancer Therapy
ISBN: 9783030093365
Издательство: Springer
Классификация:

ISBN-10: 3030093360
Обложка/Формат: Soft cover
Страницы: 401
Вес: 0.63 кг.
Дата издания: 2018
Серия: Cancer Drug Discovery and Development
Язык: English
Издание: Softcover reprint of
Иллюстрации: 60 tables, color; 52 illustrations, color; 28 illustrations, black and white; ix, 401 p. 80 illus., 52 illus. in color.
Размер: 234 x 156 x 21
Читательская аудитория: General (us: trade)
Основная тема: Biomedicine
Ссылка на Издательство: Link
Рейтинг:
Поставляется из: Германии
Описание: Over the past decade a complex role for DNA damage response (DDR) in tumorigenesis has emerged. A proficient DDR has been shown to be a primary cause for cellular resistance to the very many DNA damaging drugs, and IR, that are widely used as standard-of-care across multiple cancer types. It has also been shown that defects in this network, predominantly within the ATM mediated signaling pathway, are commonly observed in cancers and may be a primary event during tumorigenesis. Such defects may promote a genomically unstable environment, facilitating the persistence of mutations, any of which may provide a growth or survival advantage to the developing tumor. In addition, these somatic defects provide opportunities to exploit a reliance on remaining repair pathways for survival, a process which has been termed synthetic lethality. As a result of all these observations there has been a great interest in targeting the DDR to provide anti-cancer agents that may have benefit as monotherapy in cancers with high background DNA damage levels or as a means to increase the efficacy of DNA damaging drugs and IR. In this book we will review a series of important topics that are of great interest to a broad range of academic, industrial and clinical researchers, including the basic science of the DDR, its role in tumorigenesis and in dictating response to DNA damaging drugs and IR. Additionally, we will focus on the several proteins that have been targeted in attempts to provide drug candidates, each of which appear to have quite distinct profiles and could represent very different opportunities to provide patient benefit.
Дополнительное описание:

1. Targeting DNA repair in anti-cancer treatments.- 2. The DNA damage response: roles in cancer etiology and treatment.- 3. Control of DNA Replication by ATR.- 4. Targeting ATR for cancer therapy: Profile & expectations for ATR inhibitors.- 5. Target

Targeting the DNA Damage Response for Anti-Cancer Therapy, John Pollard; Nicola Curtin